OKYO Pharma Will Present at Upcoming Medical Conferences
The biopharmaceutical firm will discuss corneal disease research at industry events in Anaheim and New Orleans.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Do you trust that pharmaceutical companies prioritize patient needs when engaging with medical experts?
OKYO Pharma, a clinical-stage biopharmaceutical firm, will detail its research on neuropathic corneal pain at major industry conferences throughout late 2026. Leadership plans to engage with eye care specialists at the American Academy of Optometry and Ophthalmology meetings.
Why it matters
The presentations aim to foster collaboration with experts who manage patients with chronic eye conditions. This outreach supports the firm's ongoing development of new therapies for anterior segment diseases.
The planned global Phase 3 clinical trial will enroll 111 patients to evaluate treatments for neuropathic corneal pain. This pivotal study is scheduled to begin in the second half of 2026.
The players
OKYO Pharma
This clinical-stage biopharmaceutical company focuses on developing innovative therapies for neuropathic corneal pain and anterior segment eye diseases.
Robert J. Dempsey
He serves as the Chief Executive Officer at OKYO Pharma and leads the strategic direction of the organization.
The details
Company leadership will discuss the critical unmet needs in treating anterior segment diseases during events in Anaheim and New Orleans. These presentations are designed to connect the organization with the optometric and ophthalmological communities that directly manage these patient populations.
Timeline
September 30 - October 1, 2026: American Academy of Optometry conference in Anaheim.
October 8, 2026: OKYO Pharma presentation at Eyecelerator in New Orleans at 1:29 PM CT.
October 9-12, 2026: American Academy of Ophthalmology conference in New Orleans.
Second half of 2026: Planned start of the Phase 3 clinical trial.
The Tech Race
The push toward Phase 3 trials signifies a critical shift within the clinical-stage biopharmaceutical development lifecycle for specialized ocular therapies. This stage marks a move from earlier research phases into larger patient trials required for potential market entry.
These conference presentations may influence the future availability of specialized treatments for patients suffering from chronic corneal pain. If the upcoming clinical trials prove successful, these new therapies could eventually provide significant relief for those managing anterior segment eye conditions.
The takeaway
Engaging with clinical experts at specialized medical conferences is a key strategy for biopharmaceutical companies preparing for pivotal trial phases. These interactions help ensure that emerging therapies are tailored to meet the specific requirements of both physicians and their patients.
What happens next
The Phase 3 clinical trial is projected to begin in the second half of 2026, pending final organizational readiness.
Further reading
Learn more about the latest industry developments in the Biotech section.
More information
Review the full OKYO Pharma corporate information for additional updates on their research programs.
Live Poll
Do you trust that pharmaceutical companies prioritize patient needs when engaging with medical experts?
